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Introduction
Breast cancer growth is regulated by estrogen, which acts
by binding to its estrogen receptor alpha (ERα). The
presence of ERα in breast tumors is used as a biological
marker to identify patients who may respond to endocrine
agents such as tamoxifen. However, one-half of the
patients with ERα-positive tumors fail to respond favorably
to antiestrogen treatment [1,2].
ABCC1 = ATP binding cassette C1 isoform; AUC = area under the curve; CYP2A6 = cytochrome P450 2A6 isoform; CYP2B6 = cytochrome
P450 2B6 isoform; ERα = estrogen receptor alpha; ESR1/ERα = estrogen receptor alpha; FMO5 = flavin-containing monooxygenase 5 isoform;
GSTM3 = glutathione S-transferase M3 isoform; MKI67 = proliferation-related Ki-67 antigen; NAT1 = N-acetyltransferase 1 isoform; PCR = poly-
merase chain reaction; ROC = receiver–operating characteristic; RT = reverse transcriptase; SULT2B1 = sulfotransferase 2B1 isoform; TBP =
TATA box-binding protein.
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Abstract
Introduction: Little is known of the function and clinical
significance of intratumoral dysregulation of xenobiotic-
metabolizing enzyme expression in breast cancer. One
molecular mechanism proposed to explain tamoxifen resistance
is altered tamoxifen metabolism and bioavailability.
Methods: To test this hypothesis, we used real-time
quantitative RT-PCR to quantify the mRNA expression of a
large panel of genes coding for the major xenobiotic-metabolizing
enzymes (12 phase I enzymes, 12 phase II enzymes and three
members of the ABC transporter family) in a small series of
normal breast (and liver) tissues, and in estrogen receptor
alpha (ERα)-negative and ERα-positive breast tumors. Relevant
genes were further investigated in a well-defined cohort of 97
ERα-positive postmenopausal breast cancer patients treated
with primary surgery followed by adjuvant tamoxifen alone.
Results: Seven of the 27 genes showed very weak or
undetectable expression in both normal and tumoral breast
tissues. Among the 20 remaining genes, seven genes
(CYP2A6, CYP2B6, FMO5, NAT1, SULT2B1, GSTM3  and
ABCC11) showed significantly higher mRNA levels in ERα-
positive breast tumors than in normal breast tissue, or showed
higher mRNA levels in ERα-positive breast tumors than in ERα-
negative breast tumors.
In the 97 ERα-positive breast tumor series, most alterations of
these seven genes corresponded to upregulations as
compared with normal breast tissue, with an incidence ranging
from 25% (CYP2A6) to 79% (NAT1). Downregulation was
rare. CYP2A6, CYP2B6, FMO5 and NAT1 emerged as new
putative ERα-responsive genes in human breast cancer.
Relapse-free survival was longer among patients with FMO5-
overexpressing tumors or NAT1-overexpressing tumors
(P = 0.0066 and P = 0.000052, respectively), but only NAT1
status retained prognostic significance in Cox multivariate
regression analysis (P = 0.0013).
Conclusions: Taken together, these data point to a role of
genes coding for xenobiotic-metabolizing enzymes in breast
tumorigenesis, NAT1 being an attractive candidate molecular
predictor of antiestrogen responsiveness.
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Several mechanisms have been forwarded to explain this
lack of response in ERα-positive patients, one being based
on altered tamoxifen metabolism or bioavailability [3–5].
Tamoxifen is metabolized by phase I enzymes such as
cytochromes P450, lactoperoxidase, microsomal epoxide
hydrolase and flavin-containing monooxygenase [6–9].
Tamoxifen metabolites may have not only antiestrogenic
activity, but also estrogenic or genotoxic actions [10–13].
These tamoxifen metabolites are secondarily detoxified by
phase II enzymes (conjugation enzymes) such as catechol-
O-methyltransferase, UDP-glucuronosyltransferases, gluta-
thione S-transferases, sulfotransferases, N-acetyltransferases
and NAD(P):quinone oxidoreductase [14–18].
The three main tamoxifen metabolites are tamoxifen-N-
oxide (catalyzed by flavin-containing monooxygenase, FMO1
and  FMO5), 4-hydroxy-tamoxifen and N-desmethyl-
tamoxifen (catalyzed by CYP2B6,  CYP2C9,  CYP2D6,
CYP2E1,  CYP3A4, etc. [7,8]). 4-Hydroxy-tamoxifen has
the strongest antiestrogen activity (100-fold higher than
tamoxifen itself) [6]. All three metabolites are secondarily
detoxified by phase II enzymes [14–18].
Most xenobiotic-metabolizing enzymes are expressed in
the liver, but some are also expressed in breast tissue.
Intratumoral tamoxifen or metabolites (generated by hepatic
metabolism) could thus undergo further transformation in
the breast in situ [19]. Altered intratumoral expression of
genes coding for xenobiotic-metabolizing enzymes is one
potential mechanism of tamoxifen resistance.
Little is known of the function and clinical significance of
the altered intratumoral expression of xenobiotic-metabo-
lizing enzymes with respect to tamoxifen resistance. Lower
tumor tamoxifen concentrations have been observed in
tamoxifen-resistant tumors from breast cancer patients
[20]. CYP1A1  and CYP1B1  expression is increased in
antiestrogen-resistant human breast cancer cell lines [21].
Fritz and colleagues [22] recently identified microsomal
epoxide hydrolase as a predictor of the tamoxifen response
in breast cancer.
To further investigate the possible relationship between
altered intratumoral expression of xenobiotic-metabolizing
enzymes and both breast tumorigenesis and tamoxifen
resistance, we used real-time quantitative RT-PCR assays to
quantify mRNA expression of a large panel of genes coding
for the major xenobiotic-metabolizing enzymes (12 phase I
enzymes, 12 phase II enzymes and three members of the
ABC transporter family involved in multidrug resistance) in a
small series of ERα-negative and ERα-positive breast
tumors. Seven relevant genes thus identified were further
investigated in a well-defined cohort of 97 ERα-positive
postmenopausal breast cancer patients treated with primary
surgery followed by adjuvant tamoxifen alone.
Materials and methods
Patients and samples
We analyzed tissue samples from primary breast tumors
excised from 97 women at Centre René Huguenin from
1980 to 1994. The tumor samples were stored in liquid
nitrogen immediately following surgery until RNA extraction.
The patients (mean age, 71.1 years; range, 54–86 years)
met the following criteria: primary unilateral nonmetastatic
postmenopausal breast carcinoma; ERα-positive as
determined at the protein level by biochemical methods
(Dextran-coated charcoal method until 1988 and enzyme
immunoassay thereafter) and at the mRNA level by ESR1/
ERα real-time quantitative RT-PCR assay [23]; complete
histological and biological information available from the
primary tumors; no radiotherapy or chemotherapy before
surgery; and clinical follow-up at Centre René Huguenin.
The standard prognostic factors are presented in Table 1.
Thirty-one patients (32.0%) had modified radical mastec-
tomy and 66 patients (68.0%) had breast-conserving
surgery plus locoregional radiotherapy. Patients under-
went physical examinations and routine chest radiography
every 3 months for 2 years, and then annually. Mammo-
grams were performed annually. The median follow-up
was 6.5 years (range, 1.5–17.7 years). All the patients
received postoperative adjuvant endocrine therapy (20 mg
tamoxifen daily for 3–5 years), and no other treatment.
Thirty-two patients relapsed (the distribution of first relapse
events was 27 distant metastases, and five patients with
both local and/or regional recurrences and metastases).
Five ERα-negative tumors were also analyzed in order to
investigate the relationship between target mRNA levels
and ERα expression status.
Specimens of adjacent normal breast tissue from five breast
cancer patients (patients who did not belong to the series
of 97 patients analyzed in this study), and normal breast
tissue from three women undergoing cosmetic breast
surgery, were used as sources of normal breast RNA.
As xenobiotic-metabolizing enzymes are mainly expressed
in the liver, we also analyzed a pool of mRNA from three
normal human livers (Clontech, Palo Alto, CA, USA) in
order to compare mRNA levels between normal breast
and liver tissues.
Real-time RT-PCR
Theoretical basis
Quantitative values are obtained from the cycle number
(Ct value) at which the increase in fluorescent signal
associated with an exponential growth of PCR products
starts to be detected by the laser detector of the ABI
Prism 7700 Sequence Detection System (Perkin-Elmer
Applied Biosystems, Foster City, CA, USA). This was
done using the PE Biosystems analysis software
according to the manufacturer’s manuals.Breast Cancer Research    Vol 6 No 3 Bièche et al.
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The precise amount of total RNA added to each reaction
mix (based on optical density) and its quality (i.e. lack of
extensive degradation) are both difficult to assess. We
therefore also quantified transcripts of the gene coding for
the TATA box-binding protein (TBP) (a component of the
DNA-binding protein complex TFIID) as the endogenous
RNA control, and each sample was normalized on the
basis of its TBP content.
Results, expressed as n-fold differences in target gene
expression relative to the TBP gene (termed ‘Ntarget’),
were determined by the formula: Ntarget = 2∆Ctsample,
where the ∆Ct value of the sample was determined by
subtracting the average Ct value of the target gene from
the average Ct value of the TBP gene.
The Ntarget values of the samples were subsequently
normalized such that the mean of the Ntarget values of the
eight normal breast samples would equal a value of 1.
Target gene mRNA levels were confirmed using an
additional endogenous RNA control for normalization; that
is, the gene PPIA coding for the peptidylprolyl isomerase
A (cyclophilin A).
Primers
Primers for the 27 xenobiotic-metabolizing target genes,
the ESR1/ERα gene (coding for the ERα) and the MKI67
gene (coding for the proliferation-related Ki-67 antigen)
were chosen with the assistance of the computer program
Oligo 5.0 (National Biosciences, Plymouth, MN, USA).
We conducted BLASTN searches against ‘dbEST’, ‘htgs’
and ‘nr’ (the nonredundant set of the GenBank, EMBL and
DDBJ database sequences) to confirm the total gene
specificity of the nucleotide sequences chosen for the
primers, and to confirm the absence of DNA poly-
morphisms. In particular, the primer pairs were selected to
be unique when compared with the sequences of the
closely related family member genes or of corresponding
retropseudogenes. To avoid amplification of contami-
nating genomic DNA, one of the two primers was placed,
if possible, in a different exon. For example, the upper
primer of TBP was placed at the junction between exons
5 and 6, whereas the lower primer was placed in exon 6.
In general, amplicons were between 70 and 120
nucleotides. Agarose gel electrophoresis allowed us to
verify the specificity of PCR amplicons.
The 27 target genes tested in this study are presented in
Table 2. The nucleotide sequences of the primers are
available on request.
RNA extraction
Total RNA was extracted from breast specimens using the
acid–phenol guanidinium method. The quality of the RNA
samples was determined by electrophoresis through
agarose gels and staining with ethidium bromide. The 18S
and 28S RNA bands were visualized under ultraviolet
light.
cDNA synthesis
RNA was reverse transcribed in a final volume of 20 µl
containing 1 × RT buffer (500 µM each dNTP, 3 mM
MgCl2, 75 mM KCl, 50 mM Tris–HCl; pH 8.3), 20 U
RNasin Ribonuclease inhibitor (Promega, Madison, WI,
USA), 10 mM dithiothreitol, 100 U Superscript II RNase
H-reverse transcriptase (Gibco BRL, Gaithersburg, MD,
USA), 3 µM random hexamers (Pharmacia, Uppsala,
Sweden) and 1 µg total RNA. The samples were
incubated at 20°C for 10 min and at 42°C for 30 min, and
RT was inactivated by heating at 99°C for 5 min and
cooling at 5°C for 5 min.
PCR amplification
All PCR reactions were performed using an ABI Prism
7700 Sequence Detection System (Perkin-Elmer Applied
Biosystems). PCR was performed using the SYBR®
Green PCR Core Reagents kit (Perkin-Elmer Applied
Biosystems). The thermal cycling conditions comprised an
initial denaturation step at 95°C for 10 min and 50 cycles
at 95°C for 15 s and at 65°C for 1 min.
Table 1
Characteristics of the 97 postmenopausal patients with
estrogen receptor alpha-positive breast tumors and relation to
relapse-free survival
Relapse-free survival 
Number of  Relapses 
patients (%) Pa
Age
≤ 70 years 47 18 (40.0) NS (0.89)
> 70 years 50 14 (26.5)
Histological gradeb,c
I + II 77 20 (26.0) 0.0057
III 19 11 (57.9)
Lymph node status
0 16 1 (6.2) 0.0018
1–3 52 15 (28.8)
> 3 29 16 (55.2)
Macroscopic tumor sizec
≤ 30 mm 66 18 (27.3) 0.028
> 30 mm 30 14 (46.7)
Estrogen receptor alpha RNA status
Low 33 16 (48.5) NS (0.078)
Intermediate 32 6 (18.8)
High 32 10 (31.2)
Estrogen receptor beta RNA status
Low 33 5 (15.1) NS (0.062)
Intermediate 32 14 (43.8)
High 32 13 (40.6)
a P value, log-rank test. NS, not significant. b Scarff Bloom Richardson
classification. c Information available for 96 patients.Statistical analysis
The distribution of mRNA levels was analyzed on the
basis of their median values and ranges. Relationships
between mRNA levels of the different target genes, and
comparisons between median target gene mRNA levels
and clinical, histological and biological parameters were
based on nonparametric tests — namely the Mann–
Whitney test (link between one qualitative parameter and
one quantitative parameter) and the Spearman rank
correlation test (link between two quantitative
parameters). Differences between two populations were
judged significant at confidence levels greater than 95%
(P < 0.05).
To visualize the capacity of target gene mRNA levels to
discriminate between patients who relapsed and those
who did not relapse (in the absence of an arbitrary cutoff
value), we used the receiver–operating characteristic
Available online http://breast-cancer-research.com/content/6/3/R252
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Table 2
Target genes tested
Genbank accession  Chromosomal 
Genea number location Description
Phase I enzymes
CYP1A1 NM_000499 15q24.1 Cytochrome P450, subfamily IA, polypeptide 1
CYP1A2 NM_000761 15q24.2 Cytochrome P450, subfamily IA, polypeptide 2
CYP1B1 NM_000104 2p21 Cytochrome P450, subfamily IB, polypeptide 1
CYP2A6 NM_000762 19q13.2 Cytochrome P450, subfamily IIA, polypeptide 6
CYP2B6 NM_000767 19q13.2 Cytochrome P450, subfamily IIB, polypeptide 6
CYP2C9 NM_000771 10q24.1 Cytochrome P450, subfamily IIC, polypeptide 9
CYP2D6 NM_000106 22q13.1 Cytochrome P450, subfamily IID, polypeptide 6
CYP2E1 NM_000773 10q24.3-qter Cytochrome P450, subfamily IIE, polypeptide 1
CYP3A4 NM_017460 7q22.1 Cytochrome P450, subfamily IIIA, polypeptide 4
FMO1 NM_002021 1q23-q25 Flavin-containing monooxygenase 1
FMO5 NM_018578 1q21 Flavin-containing monooxygenase 5
LPO XM_042207 17q23.1 Lactoperoxydase
Phase II enzymes
NQO1 NM_000903 16q22.1 NAD(P)H deshydrogenase, quinone 1
NAT1 NM_000662 8p23.1-p21.3 N-acetyltransferase 1
COMT NM_000754 22q11.21 Catechol-O-methyltransferase
EPHX1 NM_000120 1q42.1 Epoxyde hydrolase 1, microsomal
SULT1A1 NM_001055 16p12.1 Sulfotransferase family, cytosolic, 1A, member 1
SULT2A1 NM_003167 19q13.3 Sulfotransferase family, cytosolic, 2A, member 1
SULT2B1 NM_004605 19q13.3 Sulfotransferase family, cytosolic, 2B, member 1
UGT1A1 NM_000463 2q37 UDP-glucuronosyltransferase, 1 family, polypeptide A1
GSTP1 NM_000852 11q13 Glutathion S-transferase pi 1
GSTM1 NM_000561 1p13.3 Glutathion S-transferase mu 1
GSTM3 NM_000849 1p13.3 Glutathion S-transferase mu 3
GSTT1  NM_000853 22q11.23 Glutathion S-transferase theta 1
Phase III proteins
ABCB1 NM_000927 7q21.1 ATP-binding cassette, subfamily B (MDR/TAP), member 1 (MDR1)
ABCC1 NM_004996 16p13.1 ATP-binding cassette, subfamily C (CFTR/MRP), member 1 (MRP1)
ABCC11 NM_033151 16q12.1 ATP-binding cassette, subfamily C (CFTR/MRP), member 11 (MRP8)
a LocusLink symbol.(ROC)–area under the curve (AUC) method [24]. When a
molecular marker has no discriminatory value, the ROC
curve lies close to the diagonal and the AUC value is
close to 0.5. When a marker has strong discriminatory
value, the ROC curve moves to the upper left-hand corner
(or to the lower right-hand corner) and the AUC value is
close to 1.0 (or to 0).
Relapse-free survival was determined as the interval
between diagnosis and detection of the first relapse.
Survival distributions were estimated by the Kaplan–Meier
method [25], and the significance of differences between
survival rates was ascertained using the log-rank test.
Cox’s proportional hazards regression model [26] was
used to assess prognostic significance.
Results
mRNA expression of the 27 target genes in normal
breast and liver tissue, and in ERα α-negative and
ERα α-positive breast tumors
We analyzed the mRNA expression of 27 xenobiotic-
metabolizing-enzyme genes, and the MKI67  and
ESR1/ERα genes, in a pool of normal liver tissue, in eight
normal breast tissues, in five ERα-negative breast tumors
and in 17 ERα-positive breast tumors.
Target gene mRNA levels were very low (detectable but
not quantifiable by real-time quantitative RT-PCR assay,
Ct > 35) in both normal and tumoral breast tissues for
seven genes (CYP1A1, CYP1A2, CYP2C9, CYP3A4,
LPO, SULT2A1 and UGT1A1) out of the 27 xenobiotic-
metabolizing enzyme genes. CYP1A2, LPO and UGT1A1
were very weakly expressed (Ct > 35) in the pooled liver
tissues, while the other four genes (CYP1A1, CYP2C9,
CYP3A4  and  SULT2A1) showed significant expression
(Ct < 30).
Means (± standard deviation) and ranges of mRNA levels
for the 20 xenobiotic-metabolizing enzyme genes expressed
in breast tissues, as well as for ESR1/ERα and for MKI67,
are presented in Table 3. Target gene mRNA levels in the
five ERα-negative breast tumors and in the 17 ERα-
positive breast tumors (and in the pool of normal liver
tissue) are expressed relative to the mean mRNA levels
observed in the eight normal breast tissues.
From among the 20 xenobiotic-metabolizing enzyme genes,
we selected seven genes of interest for further expression
analysis in a large series of breast tumors (Table 3 and
Fig. 1). These seven genes comprised four genes signifi-
cantly upregulated in ERα-positive breast tumors as
compared with normal breast tissue (i.e. CYP2B6, NAT1,
SULT2B1  and  ABCC11), and three additional putative
ER-responsive genes (CYP2A6, FMO5 and GSTM3) that
were significantly upregulated in ERα-positive tumors
compared with ERα-negative tumors.
It is noteworthy (Table 3) that CYP1B1 and CYP2D6 were
significantly upregulated in ERα-negative tumors compared
with ERα-positive tumors, identifying them as candidate
markers of tumor aggressiveness in ERα-negative human
breast cancer.
Among the 20 xenobiotic-metabolizing enzyme genes,
only FMO5 showed markedly higher mRNA levels (>10-
fold) in liver tissue than in breast tissue. CYP1B1, NQO1
and SULT2B1, however, showed markedly lower mRNA
levels (>10-fold) in liver tissue than in breast tissue. The
other 16 genes showed close similar mRNA levels in the
liver and the breast.
The mRNA levels of these 20 genes (except for CYP2D6;
r= +0.453, P= 0.033, Spearman rank correlation test) were
not associated with the MKI67 mRNA level (a proliferation-
related marker), suggesting that they are not upregulated in
rapidly proliferating cells in vivo (data not shown).
GSTM1 and/or GSTT1 mRNA was undetectable in some
samples of both normal and tumoral breast tissue,
probably owing to the particular polymorphism of these
two genes (total absence of the two allele copies for these
loci in ‘allele null’ patients).
The Ntarget values (calculated as described in Materials
and methods) presented in Table 3 are based on the
amount of target messenger relative to the TBP endo-
genous control, in order to normalize the amount and
quality of total RNA; similar results were obtained with a
second endogenous RNA control (PPIA) coding for
cyclophilin A (data not shown).
mRNA expression of seven selected genes in 97
ERα α-positive breast tumors
We quantified mRNA levels of the CYP2A6, CYP2B6,
FMO5, NAT1, SULT2B1, GSTM3 and ABCC11 genes in
a well-defined cohort of 97 ERα-positive breast tumors
from postmenopausal patients treated by surgery who
only received tamoxifen hormonotherapy thereafter.
The ranges, means and medians of the mRNA levels of the
seven target genes in this series of 97 breast tumors are
summarized in Table 4. Major interindividual differences in
mRNA levels (at least two orders of magnitude) were
observed for all seven genes. For example, NCYP2B6 values
ranged from 0.03 to 1053.1 (i.e. more than four orders of
magnitude).
The cutoff points for altered gene expression in malignant
breast tissues were determined using the Ntarget values
(calculated as described in Materials and methods)
obtained for the eight normal breast RNA samples. The
mean values for the eight normal breast Ntarget plus five
standard deviations were considered to represent the
Breast Cancer Research    Vol 6 No 3 Bièche et al.
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eight normal breast Ntarget minus two standard deviations
(or Ntarget value = 0.1 when the latter calculation gave a
negative value) were considered to represent the cutoff
point for underexpression. The percentage of tumors
overexpressing and underexpressing the seven genes is
presented in Table 4. It is noteworthy that most alterations
corresponded to overexpression (from 25% of the tumors
for  CYP2A6  to 79% for NAT1) and rarely to under-
expression (from 0% for NAT1 and SULT2B1 to 15% for
CYP2A6).
Relationships between mRNA values of the seven
selected genes in 97 ERα α-positive breast tumors
Using the Spearman rank correlation test (which
compares continuous variables), we found a strong
positive correlation between CYP2A6, CYP2B6, FMO5
and  NAT1  mRNA levels (Table 5). We also quantified
ESR1/ERα mRNA levels in this series of 97 ERα-positive
breast tumors. We found a strong positive correlation with
CYP2A6, CYP2B6, FMO5 and NAT1 mRNA levels and,
to a lesser extent, with GSTM3 mRNA levels.
Prognostic value of the seven selected genes in 97
ERα α-positive breast tumors
The comparison of median mRNA levels in tumors from
patients without relapse (n= 65) and in tumors from patients
with relapse (n = 32) identified significant differences in
the expression of three genes (CYP2B6, FMO5 and
NAT1) (Table 6). The three genes showed lower mRNA
levels in the patients who relapsed than in those who did
not relapse. The prognostic performance of each of the
Available online http://breast-cancer-research.com/content/6/3/R252
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Table 3
mRNA levelsof MKI67, ESR1/ERα α and the 20 target genes expressed in breast tissues
Group III  Group III 
Normal breast  ERα-negative breast  ERα-positive breast  vs vs
tissues, group I (n = 8) tumors, group II (n = 5) tumors, group III (n = 17) group I group II
Normal 
Gene liver tissue Mean ± SD Range Mean ± SD Range Mean ± SD Range Pa Pa
CYP1B1 0.02 1.0b ± 0.3 0.5–1.3 11.2b ± 18.5 0.6–43.9 2.0b ± 2.8 0.3–11.8 NS 0.033
CYP2A6 9.8 1.0 ± 1.2 0.2–3.8 0.3 ± 0.1 0.1–0.4 737.9 ± 1931.2 0.01–7228.8 NS 0.048
CYP2B6 0.12 1.0 ± 0.8 0.1–2.3 0.2 ± 0.1 0.03–0.24 73.3 ± 87.7 0.8–249.8 0.0023 0.0090
CYP2D6 5.8 1.0 ± 0.6 0.3–1.7 3.4 ± 2.8 1.0–8.3 1.0 ± 0.6 0.3–2.3 NS 0.0054
CYP2E 0.97 1.0 ± 0.4 0.6–1.4 0.8 ± 0.5 0.2–1.4 1.5 ± 1.2 0.3–4.2 NS NS
FMO1 4.7 1.0 ± 0.4 0.6–1.4 0.6 ± 0.5 0.2–1.3 0.6 ± 0.5 0.1–2.0 NS NS
FMO5 28.5 1.0 ± 0.3 0.5–1.6 1.4 ± 2.1 0.2–5.1 3.4 ± 3.2 0.2–12.2 NS 0.042
NAT1 1.2 1.0 ± 0.3 0.5–1.5 0.5 ± 0.4 0.1–1.0 24.1 ± 29.0 1.2–105.2 0.0031 0.0009
COMT 0.47 1.0 ± 0.2 0.8–1.3 2.2 ± 1.5 0.3–4.3 0.9 ± 0.5 0.3–2.3 NS NS
NQO1 0.009 1.0 ± 0.9 0.2–2.8 0.9 ± 0.9 0.1–2.0 1.4 ± 1.5 0.1–5.2 NS NS
EPHX1 0.75 1.0 ± 0.9 0.2–2.1 0.3 ± 0.3 0.1–0.8 0.4 ± 0.3 0.1–1.0 NS NS
SULT1A1 1.8 1.0 ± 0.7 0.3–1.6 0.6 ± 0.5 0.1–1.2 1.1 ± 0.9 0.4–3.3 NS NS
SULT2B1 0.001 1.0 ± 1.0 0.0–2.9 1.7 ± 1.4 0.1–3.3 6.9 ± 6.9 0.4–24.0 0.0094 NS
GSTP1 0.54 1.0 ± 0.5 0.7–1.7 2.4 ± 4.0 0.2–9.4 0.9 ± 0.4 0.1–1.6 NS NS
GSTM1 0.27 1.0 ± 1.2 0.0–2.6 0.05 ± 0.11 0.0–0.2 0.5 ± 1.1 0.0–4.3 NS NS
GSTM3 0.23 1.0 ± 0.4 0.5–1.6 0.8 ± 1.3 0.1–3.0 2.7 ± 2.6 0.2–9.3 NS 0.011
GSTT1 0.35 1.0 ± 0.9 0.0–2.3 0.4 ± 0.3 0.1–0.7 0.6 ± 0.6 0.0–2.2 NS NS
ABCB1 1.6 1.0 ± 1.2 0.4–2.8 0.3 ± 0.1 0.01–0.4 0.4 ± 0.4 0.1–1.3 NS NS
ABCC1 0.16 1.0 ± 0.3 0.8–1.3 1.0 ± 0.7 0.3–2.2 0.9 ± 0.4 0.2–1.7 NS NS
ABCC11 0.25 1.0 ± 0.9 0.4–3.3 31.2 ± 39.0 0.1–81.0 26.8 ± 36.8 0.1–108.3 0.039 NS
MKI67 70.3 1.0 ± 0.9 0.2–2.1 17.4 ± 6.6 10.0–26.6 13.0 ± 9.1 2.6–31.8 0.0023 NS
ESR1/ERα 0.002 1.0 ± 0.3 0.6–1.3 0.03 ± 0.02 0.01–0.05 29.6 ± 23.2 7.2–76.7 0.0023 0.0009
ERα, estrogen receptor alpha; SD, standard deviation. a P value, Mann–Whitney test. NS, not significant. b Mean of mRNA levels as determined in
Materials and methods.seven selected genes for relapse was assessed using
ROC curves. The overall prognostic value of these candi-
date molecular markers was compared using their AUC
values, which identified NAT1 (AUC–ROC, 0.24) as the
most discriminatory gene (Table 6).
Univariate and multivariate prognostic analyses were then
applied to CYP2B6, FMO5 and NAT1 status according to
patient survival. As the percentage of patients with
CYP2B6-overexpressing and NAT1-overexpressing tumors
was high (76% and 79%, respectively; Table 4), the
overexpressing tumors were subdivided into two equal
subgroups with moderate and strong overexpression for
univariate analysis (log-rank test). This analysis showed
that longer relapse-free survival was linked to NAT1
overexpression (P = 0.000052; Fig. 2a) and to FMO5 over-
expression (P = 0.0066; Fig. 2b). With regard to the two
subgroups of NAT1-overexpressing tumors, the higher the
NAT1 mRNA level, the better the outcome (Fig. 2a).
Relapse-free survival was not significantly associated with
CYP2B6 mRNA status (P = 0.078; Fig. 2c).
Multivariate analysis (Cox proportional hazards model) was
used to assess the influence of NAT1 and FMO5 mRNA
status on relapse-free survival, together with classical prog-
nostic parameters identified by univariate analysis (histo-
pathological grade, lymph node status and macroscopic
tumor size) in this same series of patients (Table 1). Only
NAT1 mRNA status and lymph node status retained their
prognostic significance (Table 7; P= 0.0013 and P= 0.016,
respectively).
Discussion
To test the hypothesis that altered tamoxifen metabolism
and bioavailability could explain some cases of resistance,
and to identify new candidate molecular markers to
predict antiestrogen responsiveness in breast cancer, we
used real-time quantitative RT-PCR to measure the
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Figure 1
mRNA expression levels of the seven selected genes. (a) Comparison between normal breast versus estrogen receptor alpha (ERα)-positive
breast tumors. (b) Comparison between ERα-negative versus ERα-positive breast tumors. P value, Mann–Whitney test. Box central bar, median
mRNA level.Available online http://breast-cancer-research.com/content/6/3/R252
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Table 4
mRNA levels of seven selected genes in 97 estrogen receptor alpha-positive breast tumors
mRNA levels Expression status
Gene Mean ± SD Median Range Underexpresseda Normal Overexpressedb
CYP2A6 344.0c ± 1540.6 0.9 0.001–9741.1 15 (15.5)d 58 (59.8)d 24 (24.7)d
CYP2B6 103.3 ± 172.7 37.0 0.03–1053.1 1 (1.0) 22 (22.7) 74 (76.3)
FMO5 5.2 ± 6.3 2.6 0.10–30.1 1 (1.0) 43 (44.3) 53 (54.7)
GSTM3 3.1 ± 3.5 2.0 0.07–21.2 2 (2.1) 60 (61.8) 35 (36.1)
SULT2B1 7.5 ± 10.5 4.5 0.17–84.4 0 61 (62.9) 36 (37.1)
NAT1 46.5 ± 55.4 21.5 1.1–295.6 0 20 (20.6) 77 (79.4)
ABCC11 37.1 ± 60.4 15.9 0.04–461.7 3 (3.1) 27 (27.8) 67 (69.1)
a Less than mean values for the normal breast Ntarget minus two standard deviations (SDs) (or Ntarget value = 0.1 when the latter calculation gave
a negative value). b Greater than mean values for the normal breast Ntarget plus five SDs. c The n-fold differences in target gene expression relative
to the TATA box-binding protein (TBP) gene and the normal breast tissues. d Number of patients (percentage).
Table 5
Relationships between mRNA values of the seven selected genes and the ERα α gene in the 97 estrogen receptor alpha (ERα α)-
positive breast tumor series
CYP2B6 FMO5 NAT1 SULT2B1 GSTM3 ABCC11 ESR1/ERα
CYP2A6 + 0.471  + 0.171  + 0.248  + 0.084  – 0.037  – 0.173  + 0.281 
[< 0.001] [NS (0.091)] [0.014] [NS (0.42)] [NS (0.72)] [NS (0.086)] [0.0053]
CYP2B6 + 0.525  + 0.433  + 0.083  + 0.022  + 0.022  + 0.409 
[< 0.001] [< 0.001] [NS (0.42)] [NS (0.83)] [NS (0.82)] [< 0.001]
FMO5 + 0.420  – 0.099  – 0.008  + 0.216  + 0.316 
[< 0.001] [NS (0.34)] [NS (0.93)] [0.032] [0.0018]
NAT1 + 0.077  + 0.104  + 0.041  + 0.293 
[NS (0.46)] [NS (0.31)] [NS (0.69)] [0.0037]
SULT2B1 + 0.232  + 0.049  + 0.091 
[0.021] [NS (0.64)] [NS (0.38)]
GSTM3 + 0.198  + 0.239 
[0.049] [0.018]
ABCC11 + 0.023 
[NS (0.82)]
Data presented as Spearman rank correlation coefficient [P value (Spearman rank correlation test)]. NS, not significant.
Table 6
Relationships between the prognostic (± relapses) and the mRNA levels of the seven selected genes in 97 estrogen receptor
alpha-positive breast tumors
Gene Tumors without relapses (n = 65) Tumors with relapses (n = 32) Pa ROC–AUCb
CYP2A6 1.2 (0.001–9741.1)c 0.8 (0.01–7228.8) NS (0.17) 0.41 (0.29–0.54)d
CYP2B6 56.1 (0.3–1053.1) 14.7 (0.03–249.8) 0.011 0.34 (0.23–0.45)
FMO5 3.9 (0.2–30.1) 1.4 (0.1–23.9) 0.0016 0.30 (0.19–0.41)
GSTM3 2.1 (0.07–12.2) 1.7 (0.09–21.2) NS (0.80) 0.48 (0.35–0.62)
SULT2B1 4.9 (0.2–84.4) 3.5 (0.4–21.0) NS (0.65) 0.47 (0.35–0.59)
NAT1 35.9 (1.6–295.6) 10.0 (1.1–134.1) 0.000047 0.24 (0.14–0.35)
ABCC11 15.9 (0.06–195.5) 16.6 (0.04–461.7) NS (0.60) 0.46 (0.33–0.60)
a P value, Mann–Whitney test; NS, not significant. b Receiver–operating characteristics (ROC)–area under curve (AUC) analysis. c Median (range)
of gene mRNA levels. d AUC value (95% confidence interval).expression of a large panel of genes (n = 27) coding for
major xenobiotic-metabolizing enzymes. These 27 genes
encode 12 phase I enzymes (including CYP2C9, CYP2D6,
CYP3A4 and FMO1, known to be involved in the hepatic
metabolism of tamoxifen [6,8]), 12 phase II enzymes and
three members of the ABC transporter family involved in
multidrug resistance in a series of human breast tumors.
Real-time quantitative RT-PCR has a major advantage
over cDNA microarrays in the present setting in that it can
distinguish closely related family member genes. Indeed,
some xenobiotic-metabolizing enzyme genes are clustered
in the same chromosomal region, and their nucleotide
sequences show considerable homology. This is the case
for the genes coding for certain cytochrome P450s, UDP-
glucuronosyltransferases, glutation S-transferases and
sulfotransferases. Real-time RT-PCR can use primer pairs
that are unique relative to closely related family member
genes. It is important to study these highly homologous
genes individually, as they frequently code for enzymes
with very different substrates.
Although we did not study all existing xenobiotic-
metabolizing enzyme genes, our results nevertheless
demonstrate the usefulness of real-time RT-PCR and
identify several candidate marker genes of potential
clinical value.
Xenobiotic-metabolizing enzyme genes in breast cancer
have mainly been studied by investigating the relationship
between genetic polymorphisms and cancer susceptibility
[19]. This DNA-level approach was not suited to our aims,
as it does not distinguish between hepatic gene
expression and/or mammary gene expression.
We first quantified the mRNA expression of 27 genes
coding for major xenobiotic-metabolizing enzymes in a
small series of ERα-negative (n = 5) and ERα-positive
(n = 17) breast tumors. Seven genes of interest were then
further investigated in a well-defined cohort of 97 ERα-
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Figure 2
Relapse-free survival curves. (a) Patients with strong NAT1
overexpression (1), patients with moderate NAT1 overexpression (2)
and patients with normal NAT1 expression (3). (b) Patients with FMO5
overexpression (1) and patients with normal FMO5 expression (2). 
(c) Patients with strong CYP2B6 overexpression (1), patients with
moderate CYP2B6 overexpression (2) and patients with normal
CYP2B6 expression (3). NS, not significant.
Table 7
Multivariate analysis of relapse-free survival
Relapse-free survival
Regression RR 
Variable coefficient (95% CI) Pa
NAT1 status –0.84 0.0013
Normal expression 1
Moderate overexpression 0.43 (0.26-0.72)
Strong overexpression 0.19 (0.07-0.52)
Lymph node status +0.77 0.016
01
1–3 2.17 (1.15-4.09)
> 3 4.72 (1.33-16.7)
CI, confidence interval; RR, relative risk. a P value, Cox’s proportional
hazards regression model.positive postmenopausal breast cancer patients treated
with primary surgery followed by adjuvant tamoxifen alone.
This two-step strategy significantly limited the required
number of PCR experiments.
The results of the first step yielded the following information
about the involvement of xenobiotic-metabolizing enzymes
in breast tumorigenesis. Among the 27 genes we identified
seven genes (CYP1A1, CYP1A2, CYP2C9, CYP3A4,
LPO, SULT2A1  and  UGT1A) whose expression is very
weak or undetectable in breast tissue, in partial agreement
with published results [27–29]. In particular, the recent
study of Iscan and colleagues [30] observed marked
expression of CYP1B1, CYP2B6, CYP2D6 and CYP2E1
in breast tumors, but low expression or no expression of
CYP1A1  and  CYP3A4. The only discrepancy with our
study concerns CYP2A6 expression, which was not
observed in breast tissue by Iscan and colleagues.
The 20 remaining genes, except CYP1B1, FMO5, NQO1
and SUL2B1, showed mRNA expression variation <10-
fold between normal breast and liver. Another result was
that CYP1B1 and CYP2D6 were significantly upregulated
in ERα-negative (poorly differentiated) tumors relative to
ERα-positive tumors. These two genes would thus
correspond to markers of tumor aggressiveness.
Two genes (GSTM1  and  GSTT1) had undetectable
mRNA expression in a number of breast tumors, and in
normal breast tissues, probably owing to their particular
polymorphism (a total absence of the two allele copies of
these two loci in ‘allele null’ patients), although this needs
to be confirmed at the DNA level. It is noteworthy that
GSTM1 and GSTT1 polymorphisms are associated with
the risk of breast cancer and that inherited metabolic
variability may also influence breast cancer treatment
outcome [31–33].
Finally, we identified seven genes of interest (CYP2A6,
CYP2B6, FMO5, NAT1, SULT2B1, GSTM3  and
ABCC11) and further investigated their expression in a
larger series of ERα-positive breast tumors. These genes
either showed strong upregulation in ERα-breast tumors
compared with normal breast tissue, suggesting a role in
breast tumorigenesis, and/or showed upregulation in the
ERα-positive tumors compared with the ERα-negative
tumors, making them putative ERα-responsive genes.
It is noteworthy that due to lack of expression in breast
tissue (CYP2C9 and  CYP3A4), due to no expression
differences between normal and tumoral breast tissue
(FMO1) and due to expression upregulation in ERα-
negative compared with ERα-positive breast tumors
(CYP2D6), these genes classically described to
metabolize the tamoxifen in the liver were not further
investigated in the 97 ERα-positive breast tumor series.
In the second part of this study we examined relationships
between the expression status of these seven genes and
the risk of disease recurrence and the response to
tamoxifen therapy. The results point to CYP2A6, CYP2B6,
FMO5  and  NAT1  as new ERα-responsive genes, and
point to NAT1 as an independent predictor of response to
tamoxifen. Indeed, expression levels of the CYP2A6,
CYP2B6, FMO5 and NAT1 genes were strongly linked to
ERα mRNA levels in our ERα-positive breast tumor series.
Total validation of these four genes as effective ERα-
responsive genes will require the use of classical in vitro or
in vivo expression models, and the identification of estrogen-
responsive elements within the promoters of the four genes.
The most important result of this study is that both
univariate and multivariate prognostic analysis identified
NAT1 as both an independent prognostic factor of breast
cancer relapse and as a putative predictor of the response
to tamoxifen. The predictive value of NAT1 in the response
to endocrine therapy of breast cancer must now be
confirmed in a prospective randomized study designed to
show that this parameter influences outcome only in
patients who receive adjuvant tamoxifen as compared with
untreated patients. Indeed, previous epidemiological
studies of the potential link between the NAT1 genotype,
breast cancer risk and lifestyle factors (including cooked
meat and cigarettes) showed an increased risk among
individuals with certain NAT1 alleles who eat well-cooked
meat [34]. We thus cannot rule out the possibility that the
prognostic value of NAT1 in our breast cancer series was
due to individual variations in the metabolization of
xenobiotics other than tamoxifen, influencing outcome
independently of endocrine treatment.
Human aryl N-acetyltransferases are encoded by two
genes (NAT1 and NAT2) physically linked in chromosomal
region 8p21.3-23.1. Despite their strong homology at the
amino acid level (81%), NAT1 and NAT2 enzymes have
distinct substrate specificity, although they do share
certain substrates such as aromatic and heterocyclic
amine carcinogens [35]. These enzymes also have distinct
tissue expression profiles: NAT2 is principally expressed
in human liver and intestine, while NAT1 is expressed
more ubiquitously [36]. In normal breast tissue, NAT1
enzyme levels are high, while NAT2 enzyme levels are very
low [37]. It is noteworthy that NAT1 gene expression may
reliably be studied at the mRNA level because NAT1
mRNA expression detected by RT-PCR analysis seems to
be highly associated with positive NAT1  immuno-
histochemistry staining [37]. Immunochemistry-based
studies show that NAT1 expression is strictly limited to
epithelial cells, stromal tissues showing no NAT1 staining
[37]. Few data are available on NAT1 expression in breast
tumors. A recent study showed increased NAT1 enzyme
activity in a series of 12 breast tumors as compared with
normal breast tissue [38].
Available online http://breast-cancer-research.com/content/6/3/R252
R261NAT1 overexpression was associated with good outcome
in our cohort of ERα-positive postmenopausal breast
cancer patients treated with adjuvant tamoxifen alone. We
hypothesize that strong intratumoral NAT1  expression
could lead to increased detoxification of genotoxic and/or
estrogenic tamoxifen metabolites, while having no action
on the major antiestrogenic tamoxifen metabolites such as
4-hydroxy-tamoxifen, which is again metabolized by phase
I enzymes (i.e. cytochromes P450).
Conclusions
In conclusion, this study points to a role of altered
intratumoral expression of xenobiotic-metabolizing enzyme
genes in breast tumorigenesis, identifies four putative
ERα-responsive genes (CYP2A6, CYP2B6, FMO5  and
NAT1) and points to NAT1  as an attractive candidate
molecular marker predictive of antiestrogen responsive-
ness in breast cancer. This latter hypothesis is currently
being tested in a large, prospective and homogeneous
patient cohort.
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